MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

Medicare may cover NGS-based lab-developed tests and FDA-approved/cleared NGS clinical tests for patients with myeloid malignancies or suspected myeloid neoplasms under NCD 90.2, subject to MAC local discretion. The policy explicitly excludes solid tumor NGS, ctDNA testing, and germline testing from its scope; providers must follow applicable MAC/local coverage and documentation requirements for claims.

"Next-Generation Sequencing (NGS) lab-developed tests (LDTs) and FDA-approved or -cleared clinical laboratory NGS tests are covered for evaluation of myeloid malignancies and suspected myeloid neopl..."

Sign up to see full coverage criteria, indications, and limitations.